Benzo[d]thiazole is widely used in synthetic and medicinal chemistry, and it is a component of many compounds and drugs that have several different bioactivities. Herein, we describe an elegant pathway for synthesis of methyl 4- and 5-hydroxy-2-amino-benzo[d]thiazole-6-carboxylates as building blocks that can be substituted at four different positions on the bicycle and thus offer the possibility to thoroughly explore the chemical space around the molecule studied as a ligand for the chosen target. A series of 12 new compounds was prepared using the described methods and Williamson ether synthesis.
Benzo[d]thiazole is widely used in synthetic and medicinal chemistry, and it is a component of many compounds and drugs that have several different bioactivities. Herein, we describe an elegant pathway for synthesis of methyl 4- and 5-hydroxy-2-amino-benzo[d]thiazole-6-carboxylates as building blocks that can be substituted at four different positions on the bicycle and thus offer the possibility to thoroughly explore the chemical space around the molecule studied as a ligand for the chosen target. A series of 12 new compounds was prepared using the described methods and Williamson ether synthesis.
Heterocycles
are a versatile set of scaffolds that are part of
many natural products and are commonly used in synthetic and medicinal
chemistry. They offer many ways of modification and substitution,
and thus, there is a possibility to balance the physicochemical properties
of the molecules. Benzo[d]thiazole is present in
many bioactive compounds from a number of pharmacological areas. Compounds
containing the benzo[d]thiazole heterocycle have
been described as antibacterial,[1] antifungal,[2] and anticancer agents,[3] and they have antidiabetic,[4] antidepressant,[5] anticonvulsant,[6] and
radioprotective activities,[7] as well as
neuroprotective properties useful for Alzheimer’s disease[8] and Parkinson’s disease[9] (Figure ). Riluzole is an example of a marketed drug that contains benzo[d]thiazole[10] (Figure ); it has neuroprotective,
anticonvulsant, and sedative properties[11] and is used to treat amyotrophic lateral sclerosis.[12] The benzo[d]thiazole moiety is also present
in firefly luciferin, which is responsible for the bioluminescence
of firefly species,[13] which indicates that
benzo[d]thiazole-based compounds can be used as fluorescent
probes.[14,15]
Figure 1
Representative examples of pharmacologically
active benzo[d]thiazoles. (a) Fungal lanosterol 14α-demethylase
(CYP51) inhibitor, with antifungal activity.[2] (b) Dual inhibitor of phosphoinositide 3-kinase and mammalian target
of rapamycin (mTOR), with anticancer activity.[3] (c) Peroxisome proliferator-activated receptor (PPAR)α inhibitor,
with antidiabetic activity.[4] (d) Amyloid-binding
alcohol dehydrogenase inhibitor, with anti-Alzheimer’s disease
activity.[8] (e) Riluzole, an inhibitor of
glutamatergic neurotransmission in the central nervous system, with
neuroprotective activity.[11] (f) Firefly
luciferin.[13]
Representative examples of pharmacologically
active benzo[d]thiazoles. (a) Fungal lanosterol 14α-demethylase
(CYP51) inhibitor, with antifungal activity.[2] (b) Dual inhibitor of phosphoinositide 3-kinase and mammalian target
of rapamycin (mTOR), with anticancer activity.[3] (c) Peroxisome proliferator-activated receptor (PPAR)α inhibitor,
with antidiabetic activity.[4] (d) Amyloid-binding
alcohol dehydrogenase inhibitor, with anti-Alzheimer’s disease
activity.[8] (e) Riluzole, an inhibitor of
glutamatergic neurotransmission in the central nervous system, with
neuroprotective activity.[11] (f) Firefly
luciferin.[13]Our research group has extensively studied the benzo[d]thiazole compounds in the context of the discovery of novel antibacterial
compounds.[16,17] Here, we present an efficient
method for the preparation of benzo[d]thiazoles that
can be conveniently substituted at four different positions: at the
2-amino group; at the 6-carboxy group; and at either the 4-hydroxy
or 5-hydroxy groups. These can be used as building blocks toward the
novel biologically active compounds that are urgently needed, especially
as antibacterial, antifungal, and anticancer agents. In drug discovery,
the availability of various building blocks is very important, as
these enable efficient and rapid design and synthesis of bioactive
analogues. Building blocks must be developable, and therefore, they
must contain chemically addressable functional groups that can be
further derivatized.[18,19]There are several reported
procedures to synthesize the benzo[d]thiazole bicycle
via cyclization or condensation reactions
using different catalysts (e.g., ammonium chloride, iodine, bromine,
palladium acetate, and copper catalysts) and different reaction conditions
(e.g., microwave irradiation, acidic or basic conditions, and resin-
or polymer-supported condensation).[20−26] In this paper, we describe a rapid and efficient preparation of
a set of new benzo[d]thiazole-6-carboxylates via
a cyclization reaction (see the proposed reaction mechanism below)
that uses different methyl p-aminobenzoates, potassium
thiocyanate, and bromine as reagents.[27] Furthermore, we describe a convenient synthetic pathway to obtain
first the benzo[d]thiazole bicycle with an unsubstituted
hydroxyl group, which can later be easily derivatized with different
alkyl substituents. This new approach enables more rapid generation
of a higher number of benzo[d]thiazole derivatives
than the cyclization of each methyl p-aminobenzoate
individually. In this paper, we present 12 new compounds with six
of them prepared using the new described approach.
Results and Discussion
We developed a convenient synthetic
approach toward new methyl
2-aminobenzo[d]thiazole-6-carboxylates that can carry
an −OR substituent or a free hydroxyl group on either position
4 or 5 and thus offer the possibility of O-substitution at these positions.
The synthesis of methyl 2-aminobenzo[d]thiazole-6-carboxylate
(Scheme , compound A) was selected as the model reaction. To synthesize compound A, 1 equiv of methyl 4-aminobenzoate and 4 equiv of KSCN were
dissolved in glacial acetic acid, with the mixture stirred for 45
min at room temperature, and then cooled to 10 °C. Bromine (2
equiv) was dissolved in a small amount of acetic acid and added dropwise.
The reaction mixture was then stirred at room temperature overnight.
When the reaction was over, the reaction mixture was put on ice and
basified to pH 8 using 25% NH3 solution, and the product
was isolated using filtration (see Section for detailed procedures).[27]
Scheme 1
Synthesis of Model Compound A
Reagents and conditions: (a)
KSCN (4 equiv), Br2 (2 equiv), CH3COOH, 10 °C,
then rt, 15 h, 25% aq. NH3, yield: 55%.
Synthesis of Model Compound A
Reagents and conditions: (a)
KSCN (4 equiv), Br2 (2 equiv), CH3COOH, 10 °C,
then rt, 15 h, 25% aq. NH3, yield: 55%.This general procedure for cyclization was then applied to a series
of 3- and 2-alkoxy-4-aminobenzoate compounds. The synthesis of 5a–f (Scheme ) and 11a–b (Scheme ) with different alkoxy substituents at positions
4 or 5 of the bicyclic structure proceeded as expected, with moderate
to good yields (35–95%). To obtain 4-substituted compounds 5a–f, 3-hydroxy-4-nitrobenzoic acid (1) was first converted to a methyl ester 2 using H2SO4 in methanol. Compound 2 was then
alkylated under conditions of the Williamson ether synthesis (3a–e) or the Mitsunobu reaction (3f).
The nitro group of 3a–f was reduced to amino with
catalytic hydrogenation (for 4a, 4c, 4d, and 4g) or using tin(II) chloride (for 4b and 4e). The described cyclization procedure
was applied to 4a–f to obtain the desired products 5a–f (Scheme ). For 5-substituted compounds, 7 was prepared
with Fischer esterification of 4-aminosalicylic acid (6). The amino group of 7 was protected with the tert-butyloxycarbonyl-protecting group to obtain 8, which was alkylated with methyl iodide or benzyl bromide to obtain 9a–b. The tert-butyloxycarbonyl-protecting
group was then removed by acidolysis, and finally, 10a–b that were obtained were then cyclized to 11a–b using the procedures described in Scheme .
Scheme 2
Synthesis of Compounds 5a–f
Reagents and conditions: (a)
MeOH, H2SO4, 65 °C, 15 h, yield: 94%. (b)
Corresponding alkyl halide, K2CO3, CH3CN or DMF, 60 °C, 15 h (for synthesis of 3a–e). (c) 2-Methoxyethanol, DIAD, PPh3, THF, rt, 15 h (for
synthesis of 3f), yield: 22–97%. (d) H2, Pd/C, MeOH, rt, 2–5 h (for synthesis of 4a, 4c–d, 4f). (e) SnCl2, MeOH/EtOAc,
55 °C, 15 h (for synthesis of 4b, 4e), yield: 66–99%. (f) KSCN, Br2, CH3COOH, 10 °C, then rt, 15 h, 25% aq. NH3, yield: 35–95%.
Scheme 3
Synthesis of Compounds 11a–b
Reagents and conditions: (a)
MeOH, H2SO4, 65 °C, 15 h, yield: 89%. (b)
Boc2O, 70 °C, 48 h, yield: 43%. (c) Corresponding
alkyl halide, K2CO3, CH3CN or DMF,
60–80 °C, 15 h, yield: 54–92%. (d) 4 M HCl in 1,4-Dioxane,
1,4-dioxane, rt, 3 d, yield: 51–84%. (e) KSCN, Br2, CH3COOH, 10 °C, then rt, 15 h, 25% aq. NH3, yield: 45–74%.
Synthesis of Compounds 5a–f
Reagents and conditions: (a)
MeOH, H2SO4, 65 °C, 15 h, yield: 94%. (b)
Corresponding alkyl halide, K2CO3, CH3CN or DMF, 60 °C, 15 h (for synthesis of 3a–e). (c) 2-Methoxyethanol, DIAD, PPh3, THF, rt, 15 h (for
synthesis of 3f), yield: 22–97%. (d) H2, Pd/C, MeOH, rt, 2–5 h (for synthesis of 4a, 4c–d, 4f). (e) SnCl2, MeOH/EtOAc,
55 °C, 15 h (for synthesis of 4b, 4e), yield: 66–99%. (f) KSCN, Br2, CH3COOH, 10 °C, then rt, 15 h, 25% aq. NH3, yield: 35–95%.
Synthesis of Compounds 11a–b
Reagents and conditions: (a)
MeOH, H2SO4, 65 °C, 15 h, yield: 89%. (b)
Boc2O, 70 °C, 48 h, yield: 43%. (c) Corresponding
alkyl halide, K2CO3, CH3CN or DMF,
60–80 °C, 15 h, yield: 54–92%. (d) 4 M HCl in 1,4-Dioxane,
1,4-dioxane, rt, 3 d, yield: 51–84%. (e) KSCN, Br2, CH3COOH, 10 °C, then rt, 15 h, 25% aq. NH3, yield: 45–74%.To define the reaction
mechanism, we monitored formation of 5b with HPLC–MS
analysis (Scheme ; Supporting Information, Section S1). Before the
addition of bromine, the reaction did not
start (Supporting Information, Section
S1, Figure S1), but immediately after the addition, the thiocyanate
group was attached to the phenyl ring of the starting aniline (4b; Supporting Information, Section
S1, Figure S2). Bromine was needed for the formation of the pseudohalogen
thiocyanogen (Scheme ), which was then involved in the thiocyanation of aniline.[28] After 30 min, there was no more starting aniline
in the reaction mixture (Supporting Information, Section S1, Figure S3), and the formation of intermediate I1 with the SCN group attached to the phenyl ring (Scheme ) was confirmed using
nuclear magnetic resonance (NMR) (Supporting Information, Section S1, Figure S4). After 60 min, the formation of benzo[d]thiazole 5b was detected. Although intermediate I1 and product 5b have exactly the same mass
(Supporting Information, Section S1, Figure
S5), they have different retention times in the HPLC chromatograms,
as well as significantly different chemical shifts for NH2 protons in the NMR spectra (6.40 ppm for I1; 7.91 ppm
for 5b; Supporting Information, Section S1, Figure S6). After 15 h, the reaction was complete (Supporting Information, Section S1, Figure S7),
and 5b could be isolated.
Scheme 4
Proposed Mechanism
for Formation of the Benzo[d]thiazole
Bicycle
As the cyclization of each
individual methyl p-aminobenzoate to obtain different
substituents at positions 4 and
5 was time consuming, and therefore not so efficient, we developed
a synthetic route for preparation of 4- and 5-hydroxy benzo[d]thiazoles, which could be synthesized on a large scale
and derivatized at later synthetic stages. This would provide a rapid
route for preparation of a central benzo[d]thiazole
core as a building block around which the chemical space could be
explored by the introduction of different chemical groups. To achieve
this, we first looked for a suitable hydroxyl-protecting group that
would not be cleaved under the acidic conditions that are used for
cyclization and that would be easy to remove afterward. Benzyl- and
acetyl-protecting groups were first used, but neither was optimal
because of the unsuccessful removal after cyclization (in the case
of benzyl protection), the migration of the acetyl group between OH
and NH2 (in the case of acetyl protection) or the non-regioselective
cyclization (in the case of acetyl protection). Detailed description
and results of the exploration of these protecting groups can be found
in Section S2.1 in the Supporting Information.In a novel approach, the tert-butyldimethylsilyl
group was used for protection of the hydroxyl group (Scheme ; Supporting Information, Section S2.2, Scheme S3), which was easily introduced
into the methyl 3-hydroxy-4-nitrobenzoate (2; Scheme ) using tert-butyldimethylsilyl chloride as the reagent. The nitro group of 12 (Scheme ) was reduced to the amino group using catalytic hydrogenation (13; Scheme ). The details of the exploration of the cyclization reaction using
the tert-butyldimethylsilyl-protecting group can
be found in Supporting Information, Section
S2.2. To successfully prepare the desired products, the cyclization
reaction was set up following the general procedure, although halved
amounts of KSCN and bromine (from initial 4 equiv of KSCN and 2 equiv
of Br2) were used. Using ammonia solution for the neutralization
during the isolation process resulted in successfully prepared tert-butyldimethylsilyl-protected product 14 (Scheme ) that can
be used as a convenient building block. On the other hand, using saturated
aq. NaHCO3 as the base instead of ammonia, we successfully
obtained the desired product with an unsubstituted OH group at position
4 (15; Scheme ).
Scheme 5
Synthesis of Methyl 2-Amino-4-hydroxybenzo[d]thiazole-6-carboxylate
(15) and 2-Amino-5-hydroxybenzo[d]thiazole-6-carboxylate
(18) Using the tert-Butyldimethylsilyl-Protecting
Group
Reagents and conditions: (a)
TBDMSCl, pyridine, rt, 15 h. (b) H2, Pd/C, MeOH, rt, 5
h, yield: 56%. (c) KSCN (2 equiv), Br2 (1 equiv), CH3COOH, 10 °C, then rt, 15 h, 25% aq. NH3 (for
synthesis of 14) or sat. aq. NaHCO3 (for synthesis
of 15, 17, and 18), yield:
13–60%. (d) TBDMSCl, 4-methylimidazole, DCM, rt, 96 h, yield:
75%.
Synthesis of Methyl 2-Amino-4-hydroxybenzo[d]thiazole-6-carboxylate
(15) and 2-Amino-5-hydroxybenzo[d]thiazole-6-carboxylate
(18) Using the tert-Butyldimethylsilyl-Protecting
Group
Reagents and conditions: (a)
TBDMSCl, pyridine, rt, 15 h. (b) H2, Pd/C, MeOH, rt, 5
h, yield: 56%. (c) KSCN (2 equiv), Br2 (1 equiv), CH3COOH, 10 °C, then rt, 15 h, 25% aq. NH3 (for
synthesis of 14) or sat. aq. NaHCO3 (for synthesis
of 15, 17, and 18), yield:
13–60%. (d) TBDMSCl, 4-methylimidazole, DCM, rt, 96 h, yield:
75%.The same reaction conditions were later
applied for the preparation
of benzo[d]thiazoles with an unsubstituted OH group
at position 5 (Scheme ). First, the OH group of 7 was selectively protected
with the tert-butyldimethylsilyl-protecting group
in the presence of NH2, to obtain 16, thus
avoiding an additional step of Boc-protection/deprotection. After
cyclization, a mixture of tert-butyldimethylsilyl-protected
(17) and -deprotected (18) products substituted
at position 5 was obtained (Scheme ). Apparently, the bulky silyl protection group sterically
hindered cyclization to position 7, which was observed in the case
of the acetyl-protecting group (Supporting Information, Section S2.1, Scheme S2), and this thus allowed the cyclization
to proceed only in the desired direction. The mixture of products 17 and 18 obtained after the reaction was then
easily separated. Detailed exploration and procedures for the separation
can be found in Supporting Information,
Sections S2.3 and S4. Overall, we developed a convenient new method
for preparation of both benzo[d]thiazole with an
unsubstituted 5-OH group and benzo[d]thiazole with
a tert-butyldimethylsilyl-protected 5-OH group, which
were used in the further reactions, where the hydroxy group had to
be either protected or not.A successful synthesis of the desired
hydroxybenzo[d]thiazoles 15 and 18 enabled the preparation
of a series of new compounds that were alkylated at the 4-OH or 5-OH
groups (products 5b, 19a–d, and 20; Scheme ). The etherification of the OH group could be performed selectively
in the presence of an unprotected 2-amino group, with the Williamson
ether synthesis method using different alkylating agents and K2CO3 in acetonitrile or dimethylformamide as the
solvent (Scheme ).
Scheme 6
Synthesis of Compounds 5b, 19a–d, and 20
Reagents and conditions: (a)
corresponding alkyl halide, K2CO3, CH3CN or DMF, 60–80 °C, 15 h, yield: 28–45%.
Synthesis of Compounds 5b, 19a–d, and 20
Reagents and conditions: (a)
corresponding alkyl halide, K2CO3, CH3CN or DMF, 60–80 °C, 15 h, yield: 28–45%.
Conclusions
In summary, we explored
a common procedure for cyclization of benzothiazoles
and then modified this to develop a simple method for synthesis of
methyl 2-aminobenzo[d]thiazole-6-carboxylates with
an OH group on either position 4 or 5 of the bicycle. The benzo[d]thiazole ring formation proceeded from 4-aminobenzoates
with KSCN and bromine in acetic acid. Different protecting groups
for the hydroxyl group during cyclization were explored. The best
protection/deprotection was achieved with a tert-butyldimethylsilyl
group, which can be removed easily during the isolation process. The
obtained methyl 2-amino-4-hydroxybenzo[d]thiazole-6-carboxylate
(15) and methyl 2-amino-5-hydroxybenzo[d]thiazole-6-carboxylate (18) were then selectively derivatized
on the hydroxy groups in the presence of an unprotected 2-amino group.
In the case of the 4-substituted product, we also developed two selective
isolation procedures to either remove the tert-butyldimethylsilyl-protecting
group or to keep the product protected.In conclusion, as benzo[d]thiazole is an important
scaffold in many bioactive compounds, the convenient preparation of
building blocks described in this study offers the elegant possibility
of rapidly exploring the chemical space at various positions of the
bicycle. Thus, the new products described herein can serve as useful
starting points in the synthesis of novel bioactive compounds.
Experimental Section
General Experimental Details
Chemicals
were obtained from Acros Organics (Geel, Belgium), Sigma-Aldrich (St.
Louis, MO, USA), and Apollo Scientific (Stockport, UK) and used without
further purification. Analytical TLC was performed on silica gel Merck
60 F254 plates (0.25 mm), using visualization with UV light and spray
reagents. Column chromatography was carried out on silica gel 60 (particle
size 240–400 mesh). 1H and 13C NMR spectra
were recorded at 400 and 100 MHz, respectively, on a Bruker AVANCE
III 400 spectrometer (Bruker Corporation, Billerica, MA, USA) in DMSO-d6 or CDCl3 solutions, with TMS as
the internal standard. HPLC–MS analyses were performed on an
Agilent Technologies 1260 Infinity II LC System (Agilent Technologies,
Inc., Santa Clara, CA, USA) coupled to an ADVION expression CMSL mass
spectrometer (Advion Inc., Ithaca, USA). The column used was Waters
XBridge C18 column (3.5 μm, 4.6 mm × 150 mm), a flow rate
of 1.5 mL/min, and sample injection volume of 10 μL. The mobile
phase consisted of acetonitrile (as solvent A) and 0.1% formic acid
and 1% acetonitrile in ultrapure water (as solvent B). The gradient
(for solvent A) was 0–1 min, 25%; 1–6 min, 25–98%;
6–6.5 min, 98%; 6.5–7.5 min, 98–25%; 7.5–10.5
min, 25%. Mass spectra were obtained using the Exactive Plus Orbitrap
mass spectrometer (Thermo Fisher Scientific, Waltham, Massachusetts,
ZDA) or Advion expression CMSL mass spectrometer (Advion
Inc., Ithaca, USA).
General Procedures
General Procedure A. Synthesis of Example
Compound A
To a solution of methyl 4-aminobenzoate
(500 mg, 3.31 mmol) in acetic acid (12 mL), KSCN (1.28 g, 13.2 mmol)
was added and the solution was stirred at rt for 45 min. The reaction
mixture was cooled to 10 °C, and bromine (0.339 mL, 6.62 mmol)
in acetic acid was added dropwise upon which the solution turned to
a yellow suspension. The reaction mixture was then stirred at room
temperature overnight. The reaction mixture was neutralized with 25%
aqueous NH3 solution (50 mL) to pH = 8. The precipitate
was filtered off, excessively washed with water, and dried. The solid
was suspended in methanol, heated, filtered off, and dried.
General Procedure B. Synthesis of Example
Compound 2
To a solution of 3-hydroxy-4-nitrobenzoic
acid (1, 10.0 g, 54.6 mmol) in methanol (200 mL), conc.
H2SO4 (6 mL, 112.6 mmol) was added and the mixture
was stirred at 65 °C overnight. The solvent was evaporated under
reduced pressure. The residue was neutralized with saturated aqueous
NaHCO3 solution and extracted with ethyl acetate (200 mL).
The organic phase was washed with brine (2 × 50 mL), dried over
Na2SO4, and filtered; the solvent was removed
in vacuo.
General
Procedure C. Synthesis of Example
Compound 3a
To a suspension of methyl 3-hydroxy-4-nitrobenzoate
(2, 3.00 g, 15.2 mmol) and K2CO3 (3.16 g, 22.8 mmol) in DMF (20 mL), methyl iodide (1.9 mL, 30.5
mmol) was added dropwise and the reaction mixture was stirred at 60
°C overnight. The solvent was removed in vacuo, and the residue
was dissolved in ethyl acetate (30 mL) and washed with water (2 ×
20 mL) and brine (20 mL). The organic phase was dried over Na2SO4, filtered, and the solvent was evaporated under
reduced pressure.
To a stirred solution of compound 2 (0.70 g, 3.55 mmol) and triphenylphosphine (1.86 g, 7.10
mmol) in anhydrous tetrahydrofuran (20 mL), 2-methoxyethan-1-ol (0.310
mL, 3.91 mmol) was added and the mixture was stirred at rt for 10
min. Diisopropyl azodicarboxylate (DIAD, 1.40 mL, 7.10 mmol) was added
dropwise, and the mixture was stirred at rt for 15 h under the argon
atmosphere. The solvent was evaporated in vacuo, and the residue was
purified with flash column chromatography using hexane/ethyl acetate
(2:1) as the eluent. The crude product was used in the next step without
further purification.
General
Procedure D. Synthesis of Example
Compound 4a
Methyl 3-methoxy-4-nitrobenzoate
(3a 2.98 g, 14.1 mmol) was dissolved in methanol/tetrahydrofuran
(7:3, 100 mL) under the argon atmosphere; Pd/C (500 mg) was added,
and the reaction mixture was stirred at room temperature under hydrogen
atmosphere for 5 h. The catalyst was filtered off, and the solvent
was removed in vacuo.
General Procedure E. Synthesis of Example
Compound 4b
To a solution of methyl 3-(benzyloxy)-4-nitrobenzoate
(3b, 1.48 g, 5.17 mmol) in ethyl acetate/methanol (1.5:1,
25 mL), SnCl2 (4.90 g, 25.8 mmol) was added and the reaction
mixture was stirred at 55 °C overnight. The solvent was removed
in vacuo, and to the residue, NaHCO3 (220 mL) was added
dropwise on an ice bath. The obtained white suspension was sonicated
for 30 min. Ethyl acetate was added, and the precipitate was filtered
off. The phases in the mother liquid were separated, and the water
phase was extracted with additional ethyl acetate. The precipitate
was also resuspended in ethyl acetate and filtered again. The combined
organic phases were washed with brine, dried over Na2SO4, and filtered and the solvent was removed in vacuo.
To a solution
of methyl 4-amino-2-hydroxybenzoate (9.57 g, 57.3 mmol), di-tert-butyl dicarbonate (13.8 g, 63.0 mmol) was added and
the mixture was stirred at 70 °C for 48 h. The solvent was removed
under reduced pressure; to the residue, ethyl acetate (100 mL) and
water were added, and the phases were separated. The organic phase
was washed with 1 M HCl (3 × 40 mL) and brine (3 × 40 mL),
dried over Na2SO4, filtered, and the solvent
removed in vacuo. The crude product was purified with flash column
chromatography using ethyl acetate/hexane (1:7) as an eluent. Yield:
6.52 g (43%); white crystals. 1H NMR (400 MHz, CDCl3): δ 1.54 (s, 9H), 3.94 (s, 3H), 6.62 (s, 1H), 6.95
(dd, J = 8.7, 2.2 Hz, 1H), 7.01 (d, J = 2.1 Hz, 1H), 7.76 (d, J = 8.7 Hz, 1H), 10.86
(s, 1H).
Methyl 4-Amino-2-methoxybenzoate
(10a)[34]
To a solution
of
compound 9a (0.867 g, 3.08 mmol) in dichloromethane (15
mL), trifluoroacetic acid (5 mL) was added and the reaction mixture
was stirred at rt for 4 h. To the reaction mixture, dichloromethane
(40 mL) was added and neutralized with saturated aqueous NaHCO3 solution (60 mL). The phases were separated, and the organic
phase was washed with saturated aqueous NaHCO3 solution
(2 × 35 mL) and brine (3 × 30 mL), dried over Na2SO4, filtered, and the solvent was removed in vacuo. Yield:
471 mg (84%); white crystals. mp 128–132 °C. 1H NMR (400 MHz, DMSO-d6): δ 3.66
(s, 3H), 3.71 (s, 3H), 5.94 (s, 2H), 6.14 (dd, J =
8.5, 2.0 Hz, 1H), 6.20 (d, J = 2.0 Hz, 1H), 7.50
(d, J = 8.5 Hz, 1H).
Methyl
4-Amino-2-(benzyloxy)benzoate (10b)[35]
Compound 9b (0.605 g, 1.69 mmol)
was dissolved in 2 M HCl in diethyl
ether (5 mL) and stirred at rt for 15 h. The precipitate in the reaction
mixture was filtered off and suspended in ethyl acetate (50 mL) which
was washed with saturated aqueous NaHCO3 solution (30 mL)
and brine (30 mL), dried over Na2SO4, filtered,
and the solvent was removed in vacuo. Yield: 223 mg (51%); light brown
solid. mp 111–112 °C. 1H NMR (400 MHz, DMSO-d6): δ 3.71 (s, 3H), 5.10 (s, 2H), 5.62
(br s, 2H), 6.30 (dd, J = 8.5, 2.0 Hz, 1H), 6.44
(d, J = 2.0 Hz, 1H), 7.29–7.36 (m, 1H), 7.38–7.45
(m, 2H), 7.49–7.57 (m, 2H), 7.59 (d, 1H).
To a solution of methyl 3-hydroxy-4-nitrobenzoate
(2, 2.00 g, 10.4 mmol) in pyridine (25 mL), tert-butyldimethylsilyl chloride (4.59 g, 30.4 mmol) was added. The reaction
mixture was stirred at room temperature overnight. Then, ethyl acetate
(85 mL) was added, and the solution was washed with 1 M HCl (4 ×
50 mL). The organic phase was dried over Na2SO4 and filtered, and the solvent was removed in vacuo. A crude oily
product was used in the next step without further purification.
A solution
of compound 7 (9.79 g, 58.6 mmol) in dichloromethane
(150 mL), tert-butylchlorodimethylsilane (17.7 g,
117 mmol), and 4-methylimidazole was stirred at rt 96 h. The reaction
mixture was washed with water (2 × 20 mL), and organic phases
were dried over Na2SO4 and filtered, and the
solvent was evaporated under reduced pressure. The residue was purified
with flash column chromatography using ethyl acetate/hexane (1/4)
as an eluent to give compound 17 (12.3 g) as pink-brown
crystals. Yield 12.3 g (75%); mp 64–66 °C; 1H NMR (400 MHz, DMSO-d6): δ 0.17
(s, 6H), 0.97 (s, 9H), 3.66 (s, 3H), 5.86 (s, 2H), 6.10 (d, J = 2.1 Hz, 1H), 6.18 (dd, J = 8.6, 2.1
Hz, 1H), 7.48 (d, J = 8.6 Hz, 1H). MS (ESI+) m/z: 282.2 ([M + H]+).